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The presence of chronic kidney disease in humans is associated with a risk of 
kidney function loss as well as the development of cardiovascular disease. 
Fibrocytes have been shown to contribute to organ fibrosis. In this study, the 
presence of fibrocytes was investigated immunohistochemically in kidney 
biopsy specimens from 100 patients with chronic kidney disease. In addition, 
6 patients with thin basement membrane disease were studied as a disease 
control. In patients with chronic kidney disease, the infiltration of fibrocytes 
was observed mainly in the interstitium. The number of interstitial fibrocytes 
in patients with chronic kidney disease was higher than that in patients with 
thin basement membrane disease. The number of infiltrated fibrocytes in the 
interstitium correlated well with the severity of tubulointerstitial lesions, such 
as interstitial fibrosis, in patients with chronic kidney disease. In addition, 
there were significant correlations between the number of interstitial 
fibrocytes and the number of CD68-positive macrophages in the interstitium 
as well as urinary monocyte chemoattractant protein-1/CCL2 levels. In 
particular, there was an inverse correlation between the number of interstitial 
fibrocytes and kidney function at the time of biopsy. Finally, the numbers of 
interstitial fibrocytes and macrophages as well as urinary CCL2 levels were 
significantly decreased during convalescence induced by glucocorticoid 
therapy. These results suggest that fibrocytes may be involved in the 
pathogenesis of chronic kidney disease through the interaction with 
macrophages as well as CCL2. 
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Introduction 
The presence of chronic kidney disease (CKD), manifested by low 
glomerular filtration rates (GFR) and/or urinary abnormalities, is associated with risk of 
kidney function loss leading to end-stage renal disease (ESRD). Recently, CKD has also 
been recognized as an independent risk factor of cardiovascular disease (CVD) [1]. 
Therefore, it is important to elucidate the pathophysiology of CKD. Despite varied 
etiologies, CKD progresses to ESRD through common pathological findings, including 
glomerulosclerosis and interstitial fibrosis. Especially, the severity of interstitial fibrosis 
has been reported to determine the prognosis of kidney function [2]. To date, resident 
fibroblasts, epithelial-mesenchymal transition (EMT)-derived 
fibroblasts/myofibroblasts, and monocytes/macrophages have been suggested to be 
involved in the progression of kidney diseases [3,4]. However, the precise pathogenic 
mechanisms of tubulointerstitial lesions, especially related to interstitial fibrosis, in 
patients with CKD remain to be determined. 
Recently, a circulating bone marrow-derived population of fibroblast-
like cells, termed fibrocytes, has been proposed to be a new cellular participant in the 
pathogenesis of organ fibrosis [5 – 9]. Fibrocytes express markers of leukocytes (e.g., 
CD45 and CD34) and have the ability to produce extracellular matrix proteins (e.g., type 
I collagen and fibronectin) [10,11]. The presence of fibrocytes has been demonstrated in 
experimental fibrosis associated with various conditions, such as lung, kidney, and liver 
fibrosis, as well as skin wounds [5 – 9]. Fibrocytes are also detected in human fibrosing 
disorders, including nephrogenic systemic fibrosis, bronchial asthma, and burns [12 – 
14]. Fibrocytes have been reported to express chemokine receptors such as CCR2, 
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CCR7 and CXCR4 [5,6,15,16]. In addition, fibrocytes are capable of producing various 
chemokines including monocyte chemoattractant protein (MCP)-1/CCL2 as well as 
fibrogenic cytokines (e.g., transforming growth factor (TGF)-β1) [10]. Recent studies 
demonstrated that chemokine/chemokine receptor systems are required for the 
recruitment of fibrocytes to sites of fibrosis [5,6,8,16]. However, the involvement of 
fibrocytes in the pathogenesis of human CKD has not been fully investigated. 
From these findings, we hypothesized that fibrocytes dependent on 
chemokine/chemokine receptor systems are involved in the pathogenesis of human 
CKD. To achieve this goal, we determined the presence of fibrocytes in patients with 
CKD. We also examined the association of fibrocytes infiltration with pathological 
findings as well as urinary levels of chemokines. 
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Subjects and methods 
Subjects 
One hundred patients (41 men and 59 women; median age, 50.2 years) 
with CKD were evaluated in this study (Table 1). CKD was defined as urinary 
abnormalities or GFR < 60 mL/min/1.73 m2 for 3 months or more irrespective of cause, 
as described previously [17]. Twenty-seven patients (10 men and 17 women; median 
age, 62.5 years) had crescentic glomerulonephritis (CreGN) with more than 50% of the 
total crescents (cellular, fibrocellular, and fibrous) of all glomeruli showing rapidly 
progressive glomerulonephritis (RPGN) clinically. Twenty-six patients (2 men and 24 
women; median age, 37.2 years) had lupus nephritis (LN) and were classified based on 
the glomerular appearance according to the International Society of Nephrology/Renal 
Pathology Society (ISN/RPS) 2003 classification (8 in Class II, 5 in Class III, 9 in Class 
IV, 4 in Class V) as described previously [18]. Twenty-three patients with type II 
diabetes mellitus (14 men and 9 women; median age, 55.8 years) had diabetic 
nephropathy (DN). In addition, other kidney diseases without crescents, including IgA 
nephropathy (IgA-N), obesity-related glomerulopathy (ORG), benign nephrosclerosis 
(BNS), and membranous nephropathy (MN), were also examined in this study. Six 
patients with thin basement membrane disease (TBMD; 4 men and 2 women; median 
age, 39.1 years) were included as disease controls. The patients in this study were 
chosen consecutively from May 1988 to July 2008 at Kanazawa University Hospital or 
its affiliated hospitals. All diagnoses were verified by kidney biopsy. Whenever 
possible, patients did not receive immunosuppressive agents before sample collection. 
Patients with CreGN, LN, or IgA-N in a clinically active state were treated with 
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glucocorticoids including methylprednisolone pulse therapy (500 – 1000 mg/day, 3 
days) during this study. Specimens from second biopsies were obtained from 16 patients 
with CreGN (n = 7), LN (n = 7), and IgA-N (n = 2) after glucocorticoid therapy. 
Estimated glomerular filtration rate (eGFR) was determined as reported previously [19]. 
All kidney biopsies and this study were performed with approval from the Institutional 
Review Board and on receipt of informed consent from the patients. 
 
Pathological studies 
One hundred twenty-two kidney specimens were obtained by kidney 
biopsy. Each specimen contained 10 or more glomeruli. Kidney specimens were fixed in 
10% buffered formalin (pH 7.2), embedded in paraffin, cut into sections 4 μm thick, and 
stained with hematoxylin and eosin (HE), periodic acid-Schiff (PAS) reagent, periodic 
acid silver methenamine (PAM), and Mallory-Azan. Two observers with no knowledge 
of the patients’ clinical course examined the kidney specimens by light microscopy to 
establish the diagnosis. For patients with CreGN, the percentages of crescent formation 
were evaluated. For DN patients, the severity of the diffuse lesions of glomeruli was 
graded on a scale of 0 to IV as described previously [20]. For LN patients, ISN/RPS 
2003 classification was used for light microscopic classification of LN. For all patients, 
the mean interstitial fibrotic area (blue on Mallory-Azan staining) was determined and 
expressed as percentage per square millimeter of the field using Mac Scope version 6.02 
(Mitani Shoji Co., Ltd., Fukui, Japan). Similarly, for evaluation of glomerulosclerosis, 
mean mesangial area (black on PAM staining) per glomerulus was examined from more 
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than 10 glomeruli using Mac Scope version 6.02 (Mitani Shoji Co., Ltd.) as reported 
previously [20]. 
 
Immunohistochemical studies  
Fibrocytes were identified by dual immunohistochemical techniques 
on formalin-fixed, paraffin-embedded tissue specimens using specific antibodies against 
CD45 and type I pro-collagen α1 as described previously [13]. Briefly, CD45 was 
detected by the indirect avidin-biotinylated alkaline phosphatase method using a murine 
anti-human CD45 monoclonal antibody (DAKO, Glostrup, Denmark). Type I pro-
collagen α1 (proCOLI; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was detected 
using the indirect avidin-biotinylated peroxidase complex method. In this dual 
immunostaining, the color of CD45-positive cells was red, while type I pro-collagen α1-
positive cells were brown. CD68-positive macrophages were also detected 
immunohistochemically on formalin-fixed, paraffin-embedded tissue sections by the 
indirect avidin-biotinylated alkaline phosphatase complex method using a murine anti-
human macrophage CD68 monoclonal antibody (clone KP1; DAKO). As a positive 
control, resected tonsils from patients with tonsillitis were used. Mean numbers of 
interstitial CD45/type I pro-collagen α1 dual-positive fibrocytes as well as CD68-
positive macrophages were counted from more than 10 randomly chosen fields under 
high-power magnification (×200). Two independent observers also examined the 
immunohistochemical findings without prior knowledge of chemokine levels or the 
patients’ clinical courses. 
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Measurements of urinary chemokines 
Spontaneously voided midstream urine catches were collected on the 
morning of kidney biopsy. Samples of 10 mL of the each urine specimen were spun at 
200 × g for 5 minutes at room temperature to remove cells and precipitate. The urinary 
supernatants were kept frozen at –70°C until measurement. Urinary CCL2 levels were 
determined by enzyme-linked immunosorbent assay (ELISA), using a specific murine 
monoclonal anti-human CCL2 antibody (clone ME69) for capture and a rabbit anti-
CCL2 polyclonal antibody as the second antibody, as described previously [21]. The 
recovery rate was confirmed to be more than 95% up to 3 ng/mL in these ELISA 
systems. The urinary levels of stromal cell-derived factor (SDF)-1α/CXCL12, a ligand 
for CXCR4, as well as secondary lymphoid tissue chemokine (SLC)/CCL21, a ligand 
for CCR7, were also determined using ELISA kits (R&D Systems, Minneapolis, MN). 
All assays were performed in duplicate. The detection limits of this ELISA system were 
40 pg/mL for CCL2, 18 pg/mL for CXCL12, and 9.9 pg/mL for CCL21. Urinary levels 
of these chemokines were standardized by the amount of creatinine in the urine. All 
kidney biopsies were performed with the informed consent of the patients. Urinary tract 
infections were excluded in all cases by bacterial culture, microscopic findings, or both, 





Statistical significance was analyzed using paired or unpaired Student’s t test, ANOVA, 
and Spearman’s and Pearson’s correlation coefficients for analyses of nonparametric and 
parametric data. P < 0.05 was considered to indicate statistical significance. 
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Results 
Fibrocytes infiltrating the interstitium in patients with CKD 
To determine the presence of fibrocytes, kidney samples from 100 
patients with CKD, including CreGN, LN, DN, IgA-N, ORG, MN, and BNS, and 6 
patients with TBMD were examined by immunohistochemical analyses. In patients with 
CKD, CD45/proCOLI dual-positive fibrocytes were observed mainly in the interstitium 
(Fig. 1A). The number of interstitial fibrocytes in patients with CKD was higher than 
that in patients with TBMD (8.1 ± 0.7 vs. 0.9 ± 0.4/visual field; P < 0.01, Fig. 1B). In 
contrast, fibrocytes in glomeruli were hardly observed in patients with either CKD or 
TBMD. The degree of fibrocyte infiltration in patients with CreGN (13.3 ± 1.8/visual 
field), LN (6.8 ± 1.4/visual field), DN (7.6 ± 0.9/visual field), IgA-N (3.9 ± 0.9/visual 
field) as well as BNS (4.6 ± 1.1/visual field) was more severe than that in TBMD 
patients (0.9 ± 0.4/visual field) (Table 1). In addition, the number of interstitial 
fibrocytes in patients with CreGN was higher than those in both TBMD and other forms 
of CKD (Table 1). 
 
Correlation of fibrocyte infiltration with the pathological findings 
The number of infiltrated fibrocytes in the interstitium correlated well 
with the severity of tubulointerstitial lesions, such as mean interstitial fibrotic area in 
patients with CKD (r = 0.374, P < 0.01, Table 2). In addition, there was a significant 
correlation between the number of interstitial fibrocytes and the number of CD68-
positive macrophages in the interstitium (r = 0.386, P < 0.05, Table 2). On the other 
hand, fibrocyte infiltration was not significantly correlated with the extent of 
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glomerulosclerosis in CKD patients (Table 2). In patients with CreGN, LN, and DN, the 
number of interstitial fibrocytes increased with the extent of interstitial fibrosis (r = 
0.401, P < 0.05; r = 0.545, P < 0.05; r = 0.421, P < 0.05, respectively). In glomerular 
lesions, the percentages of fibrocellular/fibrous crescents correlated well with the 
number of interstitial fibrocytes in CreGN (r = 0.453, P < 0.05). In patients with LN, the 
number of fibrocytes in Class IV was higher than in other forms of LN (11.1 ± 2.7 vs. 
5.1 ± 1.3/visual field; P < 0.05, Fig. 2A). Furthermore, the number of interstitial 
fibrocytes increased in accordance with the severity of glomerular diffuse lesions (grade 
I – II, 6.0 ± 1.1; grade III – IV, 10.2 ± 1.0; P < 0.05, Fig. 2B). 
 
Correlations between the number of fibrocytes and clinical parameters 
In patients with CKD, the number of interstitial fibrocytes increased in 
accordance with the levels of serum creatinine at the time of biopsy (r = 0.331, P < 0.05, 
Table 3). In addition, there was an inverse correlation between the number of interstitial 
fibrocytes and kidney function determined by creatinine clearance and eGFR at the time 
of biopsy (r = –0.451, P < 0.05; r = –0.352, P < 0.05, Table 3). The levels of CRP also 
correlated well with the extent of fibrocyte infiltration (r = 0.317, P < 0.05, Table 3). 
Moreover, the levels of urinary CCL2 were significantly correlated with the number of 
interstitial fibrocytes in patients with CKD (r = 0.637, P < 0.05). On the other hand, 
there were no correlations between the number of fibrocytes and the extent of 
proteinuria, hemoglobin A1c levels, or the levels of urinary CXCL12. Urinary CCL21 
protein was not detected in any cases in the present study.
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 Effects of glucocorticoid therapy on infiltration of fibrocytes and urinary CCL2 levels 
in patients with CKD 
Sixteen of fifty-two patients treated with glucocorticoid therapy 
received second renal biopsy (CreGN, n = 7; LN, n = 7; IgA-N, n = 2). The number of 
interstitial fibrocytes decreased significantly during convalescence induced by 
glucocorticoid therapy including methylprednisolone pulse therapy (before therapy 8.3 ± 
1.3 vs. after therapy 5.0 ± 1.0, P < 0.05, Fig. 3A). In addition, the number of CD68-
positive macrophages in the interstitium also decreased after glucocorticoid therapy 
(before therapy 11.2 ± 2.8 vs. after therapy 5.8 ± 1.1, P < 0.05). Similarly, elevated 
urinary CCL2 levels significantly decreased during remission induced by glucocorticoid 
therapy in the patients examined (before therapy 10.7 ± 1.4 vs. after therapy 3.1 ± 0.5 




In the present study, we investigated whether fibrocytes participate in 
the pathogenesis of human CKD. CD45/proCOLI dual-positive fibrocytes were detected 
in the interstitium in patients with CKD. In addition, the number of interstitial fibrocytes 
in CKD patients was higher than that in patients with TBMD examined as a disease 
control. The infiltrated fibrocytes number was well correlated with the extent of 
interstitial fibrosis. In particular, there were inverse correlations between the number of 
infiltrated fibrocytes in the interstitium and parameters of kidney function, such as 
serum creatinine levels, Ccr, and eGFR at the time of biopsy. Taken together, these 
results suggest that the infiltration of fibrocytes into diseased kidneys may be involved 
in the pathogenesis of human CKD, especially tubulointerstitial lesions. 
Recently, the presence of fibrocytes has been reported in various 
human fibrotic diseases, including skin, lung, and eye diseases [13,22 – 24]. In addition, 
the extent of fibrocyte infiltration into the bronchial mucosa increases in accordance 
with the severity of persistent airflow obstruction [23]. In fibrotic conditions, the 
signaling of fibrogenic cytokines such as TGF-β1 has been shown to be involved in the 
pathogenesis of organ fibrosis, including human kidney disease [25]. Fibrocytes have 
been demonstrated to produce collagen on stimulation with TGF-β1 [8,13 – 14]. In this 
study, the number of interstitial fibrocytes was significantly correlated with the extent of 
interstitial fibrosis as well as kidney function. These findings suggested that fibrocytes 
may be involved in the pathogenesis of tubulointerstitial lesions in CKD patients, at least 
in part, via collagen production. On the other hand, TGF-β1 is a well-characterized 
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inducer of EMT in tubular epithelial cells, while bone morphogenic protein-7 (BMP-7) 
counteracts TGF-β1-induced EMT, resulting in improvement of interstitial fibrosis and 
kidney function in experimental progressive kidney diseases [3]. Recent studies revealed 
that fibrocytes are capable of producing TGF-β1 under fibrotic conditions [10,15]. 
Therefore, fibrocytes may regulate EMT through the production of TGF-β1, thereby 
contributing to the pathogenesis of CKD, in addition to direct synthesis of collagen. 
Chemokines are a superfamily of small proteins that are important in 
recruiting and activating leukocytes during inflammation. Chemokines have been 
demonstrated to play important roles in the mechanisms of leukocyte entry into the 
kidneys and the activation of leukocytes in diseased kidneys [26]. CCL2, a member of 
the CC chemokine family, has been reported to play a significant role in the 
pathogenesis of human and experimental kidney diseases, especially interstitial fibrosis 
through recruitment and activation of macrophages [26 – 27]. In addition, fibrocytes are 
capable of producing CCL2 [10]. Recent studies also revealed that fibrocytes express 
various chemokine receptors, including CCR2, a cognate receptor for CCL2 [16]. 
Furthermore, the expression of type I collagen has been shown to be upregulated by 
stimulation with CCL2 in cultured fibrocytes [16]. In this study, we demonstrated that 
the number of interstitial fibrocytes was well correlated with urinary CCL2 levels as 
well as the number of interstitial CD68-positive macrophages in patients with CKD. 
Moreover, glucocorticoid therapy induced reductions in number of fibrocytes and 
CD68-positive macrophages as well as urinary CCL2 levels. Taken together, these 
observations suggest that the CCL2-dependent amplification loop for activation and 
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recruitment of fibrocytes and macrophages may be involved in the pathogenesis of 
human CKD. 
This study demonstrated no association between fibrocyte infiltration 
and the levels of urinary CXCL12. The CXCL12/CXCR4 pathway has been reported to 
be involved in the pathogenesis of pulmonary fibrosis through infiltration of fibrocytes 
[5]. Recently, CXCR4 has been demonstrated to be expressed not only on fibrocytes but 
also on various cell types, including mesenchymal stem cells [28]. Therefore, 
CXCL12/CXCR4 signaling may contribute to the mechanisms of disease progression as 
well as tissue repair. Further studies are required to elucidate the involvement of 
CCL12/CXCR4 in the pathogenesis of human kidney diseases. Furthermore, urinary 
CCL21 protein was not detected in any sample in this study. CCL21/CCR7 signaling has 
been reported to contribute to the migration of fibrocytes leading to tissue fibrosis, 
including that in the kidney [6,8]. CCL21 is a unique chemokine expressed mainly on 
vessels, thereby contributing to the infiltration of CCR7-positive cells, such as fibrocytes 
and dendritic cells [6]. Therefore, it is suggested that CCL21 is hardly secreted into the 
urine. Further studies of CCL21 expression in human kidney tissues are required. 
In this study, the number of interstitial fibrocytes was correlated well 
with the extent of interstitial fibrosis in patients with CreGN, LN, and DN. Recent 
studies revealed that mitogen-activated protein kinases (MAPKs) contribute to the 
pathogenesis of tubulointerstitial lesions in progressive kidney diseases, such as CreGN, 
LN, and DN [29 – 31]. To date, at least three distinct groups of MAPKs have been 
identified: extracellular signal-regulated kinases (ERK), p38MAPK, and c-Jun NH2-
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terminal kinase/stress-activated protein kinase (JNK/SAPK). Especially, p38MAPK is 
phosphorylated in response to hyperosmolarity, oxidative stress, and inflammatory 
cytokines, thereby contributing to the activation of nuclear transcription factors, 
including nuclear factor (NF)-κB, which principally regulates the gene expression of 
various chemokines, such as CCL2 [31]. In addition, the expression of type I collagen is 
also regulated by the MAPK family in cultured fibrocytes [32]. Taken together, these 
observations suggest that fibrocytes regulated by MAPKs may be involved in the 
pathogenesis of CKD. Further studies are needed to elucidate the effects of MAPKs on 
fibrocytes in CKD. In this study, little infiltration of fibrocytes into glomeruli was 
detected. In addition, the number of interstitial fibrocytes was not correlated with the 
index of glomerulosclerosis in all patients with CKD. However, the extent of fibrocyte 
infiltration in the interstitium was correlated with the percentages of fibrocellular/fibrous 
crescents in CreGN patients. The number of interstitial fibrocytes also increased in 
accordance with the progression of glomerular lesions in LN and DN patients. These 
findings suggest that fibrocytes are not directly involved in the pathogenesis of 
glomerular injury in patients with CKD, while fibrocyte infiltration in the interstitium 
may reflect the activity and phase of glomerular lesions in CreGN, LN, and DN. 
The clinical management of CKD remains to be investigated due to a 
lack of effective treatment or accurate indicators of disease progression. Previous 
clinical studies have shown that the renin-angiotensin system (RAS) is a major pathway 
involved in the pathogenesis of cardiovascular diseases as well as CKD [33,34]. A 
recent study indicated the expression of two isoforms of angiotensin II receptor (AT1 
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and AT2) and the effects of RAS on the expression of COLAI as well as TGF-β1 in 
cultured fibrocytes [15]. Therefore, the effects of RAS on the pathogenesis of CKD may 
be mediated, in part, by regulation of fibrocytes. Further studies are required to elucidate 
the interaction of fibrocytes with RAS in CKD. In this study, there was an inverse 
correlation between the number of interstitial fibrocytes and kidney function. In 
addition, fibrocytes numbers in peripheral blood have been reported to predict early 
mortality in patients with idiopathic pulmonary fibrosis and increase in accordance with 
the severity of asthma [23,35]. Taken together, these observations suggest that the 
number of fibrocytes in clinical samples may be useful as a biomarker for the 
progression of organ fibrosis. However, additional investigations are needed to 
determine the role of fibrocytes in CKD. 
In summary, our results suggested that the pathogenesis of human 
CKD may be closely related to fibrocyte infiltration, which may be regulated by CCL2. 
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Table 1. Patient Profiles 
Table 2. Correlation of the number of interstitial fibrocytes with pathological findings in 
CKD 
Table 3. Correlations between the number of interstitial fibrocytes and clinical 
parameters in CKD 
 
Fig. 1. Immunohistochemical examination of fibrocytes in a representative patient with 
CKD. (A) CD45/proCOLI dual-positive fibrocytes were detected mainly in the 
interstitium (arrows). CD45 (red) and proCOLI (brown). (B) The number of interstitial 
CD45/proCOLI dual-positive fibrocytes in patients with CKD was higher than that in 
TBMD patients. Bars indicate means ± SEM. 
 
Fig. 2. Increased fibrocytes in the interstitium reflect glomerular lesions in patients with 
LN and DN. (A) The number of interstitial fibrocytes in LN Class IV was higher than 
that in LN non-Class IV. (B) The number of interstitial fibrocytes increased in 
accordance with the severity of glomerular diffuse lesions in DN patients. Bars indicate 
means ± SEM. 
 
Fig. 3. Changes in the number of fibrocytes in the interstitium (A) and the levels of 
urinary CCL2 levels (B) following glucocorticoid therapy in patients with CKD. Bars 
indicate means ± SEM. 
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